Introduction {#ss1}
============

Prevention of infection is essential to increase the life expectancy of patients with renal disease. Infection in these patients leads to high morbidity and mortality, and antimicrobial therapy is often less effective than in immunocompetent hosts.[^1^](#b1){ref-type="ref"} Patients with end‐stage renal disease (ESRD) have a reduced response to vaccination because of the general suppression of the immune system associated with uraemia. Compared with vaccination in patients without ESRD, for example, dialysis patients have a lower antibody titre and an inability to maintain adequate antibody titres over time.[^2^](#b2){ref-type="ref"}, [^3^](#b3){ref-type="ref"} The relatively low antibody response to vaccines also appears to correlate with the degree of renal failure, but not with the specific mode of dialysis.[^4^](#b4){ref-type="ref"}

The altered acquired immunity in patients with ESRD may be caused by disturbances in T lymphocytes and antigen‐presenting cells, but additional studies are required.[^5^](#b5){ref-type="ref"}, [^6^](#b6){ref-type="ref"}, [^7^](#b7){ref-type="ref"} Little information has been published on the effects of dialysis adequacy on the antibody response to vaccination. There is, however, indirect evidence that increasing dialysis may be associated with an enhanced response. In a study of 32 nutritionally replete peritoneal dialysis patients immunised with the hepatitis B vaccine, the initial weekly Kt/*V* was 2·37 and 2·01 in converters and non‐converters, respectively.[^8^](#b8){ref-type="ref"}

Apparently, renal transplant recipients respond to vaccines similarly to chronic dialysis patients: the antibody response is often less than in patients without nephropathy and protective antibodies fall rapidly. Despite the evidence of decreased efficacy, current recommendations are to vaccinate patients with ESRD.[^9^](#b9){ref-type="ref"}, [^10^](#b10){ref-type="ref"} Although immunizations are important to prevent infection, many immunocompromised patients are unable to mount protective immune responses and live vaccines are usually avoided.[^11^](#b11){ref-type="ref"}

During the 2009--2010 influenza season, a monovalent vaccine was needed to vaccinate individuals against A (H1N1) pdm09, because the trivalent (seasonal) influenza vaccine did not contain antigens from this strain. When the vaccine supply was limited in the autumn of 2009, health officials created a priority list for administration of A(H1N1) pdm09 vaccine that included, amongst others, individuals with chronic renal disease because they have an increased risk of influenza complications.[^12^](#b12){ref-type="ref"}

In the present study, we evaluated the immune response to an adjuvanted A(H1N1) pdm09 vaccine (Pandemrix^®^) in four populations of renal patients (haemodialysis, renal transplantation, peritoneal dialysis and pre‐dialysis) after one and two doses of vaccination by monitoring A(H1N1) pdm09 titres. We also aimed to evaluate the influence of age, renal function, time on haemodialysis, time since the kidney transplantation, diabetes mellitus, haemoglobin levels, parathyroid hormone (PTH) levels, dialysis dose and the immunosuppressive therapy as differential factors in the immunogenecity of the vaccine amongst patients receiving these four types of renal replacement therapy.

Material and methods {#ss2}
====================

Study population {#ss3}
----------------

From November to December of 2009, a total of 151 patients were included in this study: 58 chronic haemodialysis patients, 52 renal allograft recipients, 14 peritoneal dialysis patients and 27 patients with advanced chronic kidney disease in preparation for kidney replacement therapy (GRFe MDRD‐4) lower than 20 ml/min).

Haemodialysis patients were from our in‐hospital unit, and all were receiving high‐flux haemodialysis and had optimum dialysis parameters (Kt \> 45 l).

Renal allograft recipients had been transplanted at least 6 months before the beginning of the study and had good renal function (GRFe MDRD‐4 \> 50 ml/min). All the patients had previously received the seasonal vaccination (approximately 1 month before). The main demographic, clinical and laboratory data were obtained from clinical records and are shown in [Table 1](#t1){ref-type="table-wrap"}. There were not subjects under treatment with steroids in non‐transplant patients (pre‐dialysis and dialysis groups). This study was approved by our internal ethics review board. All patients involved in the study signed the informed consent form accepted by the internal board at our centre for the antibody test.

###### 

Demographics and laboratory data

                                              Renal Transplant   Haemodialysis     Peritoneal Dialysis   Pre‐dialysis
  ------------------------------------------- ------------------ ----------------- --------------------- -----------------
  Age (years)                                 54·04 ± 12·04      59·84 ± 15        55·29 ± 14·72         70·59 ± 10·1
  Gender (male/female)                        26/26              34/24             9/5                   16/11
  Time on dialysis (months)                                      45·91 ± 56·48     25 ± 13·27             
  Time after transplantation (months)         82·58 ± 87·36                                               
  Creatinine pre‐vaccine (mg/dl)              1·44 ± 0·29                                                2·78 ± 0·82
  GFR MDRD‐4 pre‐vaccine (ml/min/1·73 m^2^)   52·42 ± 10·2                                               22·21 ± 7·27
  Diabetes mellitus (%)                       17·3               15·5              7·1                   25·9
  Serum proteins (g/l)                        6·91 ± 0·56        6·80 ± 0·59       6·80 ± 0·49           7·21 ± 0·51
  Haemoglobin (g/dl)                          12·65 ± 1·77       11·42 ± 1·52      11·95 ± 2·31          12·18 ± 1·57
  Leucocytes 10^3^/mm^3^                      7270 ± 2650        7230 ± 2110       7720 ± 2540           7370 ± 2400
  PTH (pg/ml)                                 239·06 ± 146·76    278·58 ± 216·62   381·93 ± 332·94       259·46 ± 171·86
  Kt (*l*)                                                       69·87 ± 20·44                            
  Kt/*V*                                                                           1·93 ± 0·2             
  Tacrolimus + MMF + steroids treatment       17 (32·7%)                                                  
  Sirolimus + MMF treatment                   6 (11·5%)                                                   
  Tacrolimus + MMF treatment                  7 (13·5%)                                                   
  Monotherapy (tacrolimus or sirolimus)       8 (15·4%)                                                   
  Other immunosuppressive treatment           14 (26·9%)                                                  

GFR, glomerular filtration rate; MDRD‐4, Modification of Diet in Renal Disease; PTH, parathyroid hormone; MMF, mycophenolate mofetil.

Vaccine {#ss4}
-------

All patients involved in the study received two 3·75 μg doses of adjuvant -- containing A/California/7/2009 (H1N1) v‐like strain vaccine (Pandemrix^®^) on day 0 and after 21 days. The vaccine was administered into the deltoid muscle. Information on local and general symptoms was recorded by each subject using diary cards for the first 7 days following each vaccination. Furthermore, clinical follow‐up was performed during 6 months after the vaccination.

Sample sera {#ss5}
-----------

Three sample sera were obtained from each individual, once before vaccination (time A), again at 21 days (time B: just before administration of the second dose) and at 42 days (time C: 21 days after the second dose of the vaccine) after the first dose. Sera were stored at −80°C until antibodies against A(H1N1) pdm09 were determined.

Antibody determination {#ss6}
----------------------

Influenza‐specific antibody levels were measured using a haemagglutination inhibition (HI) assay with chicken red blood cells (RBC) according to the standardized protocol of the World Health Organisation (WHO).[^12^](#b12){ref-type="ref"} In brief, serum non‐specific inhibitors were removed with receptor‐destroying enzyme treatment overnight at 37°C, followed by inactivation at 56°C for 30 min. The standard antigen was diluted to contain four haemagglutinin units, and back titration was performed. An RDE‐treated serum was two‐fold serially diluted in v‐bottom microtitre plates. Then, diluted sera were mixed with 25 μl of H1N1pdm antigen (2010--2011 WHO influenza reagent kit for the identification of influenza isolates).

After 1 h of incubation at room temperature, 50 μl of RBC \[diluted 0·05% in phosphate buffered saline (PBS)\] was added to the wells. Positive and negative serum controls were included for each plate. Titres were expressed as the reciprocal of the highest dilution of serum that inhibited haemagglutination.

The following serological parameters were evaluated:

1 Geometric mean titres (GMT) of HI.2 The seroconversion rate was defined as the rate of patients with a four‐fold increase in antibody titres against influenza A H1N1 after vaccination. Seroconversion factor was defined as the level of increase in GMT antibody titres before and after vaccination. The seroprotection rate was defined as the percentage of patients with an antibody titre of ≥1/40.[^13^](#b13){ref-type="ref"}

Statistical analysis {#ss7}
--------------------

Student's *t*‐test was used to compare continuous parameters, and the Fisher's exact test or chi‐square test for trend was used for categorical data. All *P*‐values were obtained as two sided and were considered to be significant if \<0·05. Logistic regression was used to analyse the association of clinical outcome of a protective immune response with the following parameters: age, dose of immunosuppressive agent gender, time since transplantation and panel rate antibody PRA before vaccination. Only variables with a *P*‐value \<0·15 were retained in the final model. All analyses were performed using PASW Statistics 18 software (SPSS).

Results {#ss8}
=======

Of the 151 patients included in the study, 33 (14 under haemodialysis, 5 renal transplant recipients, 6 under peritoneal dialysis and 8 with ESRD) showed seroprotection against A(H1N1) pdm09 in the pre‐vaccination sample. The main demographic and clinical data of the patients involved in this study and their immunosuppressive therapy are given in [Table 1](#t1){ref-type="table-wrap"}. There were no statistically significant differences between the four groups in age, gender, prevalence of HIV infection, prevalence of diabetes mellitus or cause of renal disease.

Geometric mean titres (GMT) of haemagglutination inhibition at Times A, B and C are shown in [Figure 1](#f1){ref-type="fig"}. The overall vaccine seroconversion rate at 21 days after the first vaccine dose (time B) was 69·8%. By groups, the seroconversion rate at this time was 79·6% in the haemodialysis group, 55·8% in the renal allograft recipient group, 80% in the advanced chronic kidney disease group and 55·6% in the peritoneal dialysis group (*P* = 0·04).

![ Geometric mean titres (GMT) of haemagglutination inhibition at Times A, B and C.](IRV-7-809-g001){#f1}

At 42 days after vaccination with the first vaccine dose and 21 days after the second dose (time C), the overall seroconversion rate was higher than after the first dose (time B) in 77·1%. By groups, the seroconversion rate at 42 days after two vaccine doses was 80% in the haemodialysis group, 64·9% in the renal allograft recipients group, 100% in the advanced chronic kidney disease group and 71·4% in the peritoneal dialysis group (*P* = 0·041). [Table 2](#t2){ref-type="table-wrap"} shows the seroprotection rates at times B and C and the seroconversion factor. At 42 days after two vaccine doses, the seroconversion and seroprotection rates were significantly lower in the transplant recipient group (*P* \< 0·05).

###### 

Seroconversion rate, seroprotection rate and seroconversion factor

                        Seroconversion Day 21   Seroconversion Day 42   Seroprotection Day 21 (%)   Seroprotection Day 42 (%)   Seroconversion Factor Day 42
  --------------------- ----------------------- ----------------------- --------------------------- --------------------------- ------------------------------
  Haemodialysis         79·6                    80                      74·1                        80                          35·5
  Renal Transplant      55·8                    64·9                    62·8                        67·7                        19·2
  Pre‐dialysis          80                      100                     85                          100                         60·1
  Peritoneal Dialysis   55·6                    71·4                    88·9                        100                         3·4
  *P*‐value             0·04                    0·041                   0·17                        0·02                        0·04

Age, gender, cause of renal disease, diabetes mellitus prevalence, serum proteins, haemoglobin level, PTH and HIV infection showed no influence on the seroconversion rate after vaccination amongst the four groups of renal patients.

In renal transplant recipients, no influence was found for time since transplantation, proteinuria, serum proteins, haemoglobin level or PTH, but immunosuppressive therapy significantly influenced the efficacy of the vaccine.

Seroconversion rates were 35·3% (6/17) in renal transplant patients using a triple therapy including a calcineurin inhibitor (CNI), mycophenolate mofetil (MMF) and steroids, 83·3% (*n*:5/6) in patients in double therapy with MMF plus a *mammalian target of rapamycin* (M‐TOR) inhibitor, 71·4% (5/7) in patients with double therapy with MMF + CNI and 87·5%(7/8) in patients under monotherapy with CNI or an M‐TOR inhibitor.

There was a statistically significant difference amongst the four immunosuppressive treatment groups (*P* = 0·02) using a chi‐square test for trend, with the lowest seroconversion rate in patients with triple therapy comparing with those on double and monotherapy. Equally, no significant differences in the efficacy of the vaccine were found in patients with double therapy receiving MMF + MTOR inhibitor vs MMF + CNI or CNI versus M‐TOR inhibitor monotherapy.

A significant difference in the seroconversion rate was observed depending on whether patients were on steroid therapy at each point in this study; 94·1% (16/17) of patients without steroid therapy achieved seroprotection after this vaccination protocol, whilst only 47·3% (9/19) of the patients under steroid therapy achieved an antibody titre of ≥1/40 (*P* = 0·003 at times B and C).

Therapy with MMF or an M‐TOR inhibitor *per se* had no statistically significant influence on the seroprotection rate.

The incidence of adverse events (local and general symptoms) at vaccination is shown in [Table 3](#t3){ref-type="table-wrap"}. No severe adverse events were detected during the follow‐up (6 months after the vaccination with the first vaccine dose). In the transplant group, no episodes of acute graft rejection have been registered.

###### 

Local and general symptoms rates at days 21 and 42

                        Local symptoms Day 21 (%)   Local symptoms Day 42 (%)   General symptoms Day 21 (%)   General symptoms Day 42 (%)
  --------------------- --------------------------- --------------------------- ----------------------------- -----------------------------
  Renal Transplant      61·51                       30·76                       40·38                         15·38
  Haemodialysis         15·51                       0                           10·34                         0
  Peritoneal Dialysis   57·14                       25·57                       35·71                         35·71
  Pre‐dialysis          37                          11·1                        18·51                         18·51

Discussion {#ss9}
==========

Based on previous experience that, like many immunocompromised patients, renal patients are unable to mount protective immune responses after vaccination, we administered two doses of the A (H1N1) pdm09 vaccine to this cohort of renal patients during the 2009--2010 influenza season.

Previous studies showed that the response to a single dose of the A (H1N1) pdm09 vaccine was suboptimal in renal transplant recipients, and a recent report has demonstrated the lack of efficacy of this schedule in a group of haemodialysis patients.[^14^](#b14){ref-type="ref"}, [^15^](#b15){ref-type="ref"} To our knowledge, this is the first study that evaluates the efficacy of this vaccine in four groups of renal patients and using two doses.

The present study showed that seroprotection before vaccination differed widely amongst these four groups of renal patients, demonstrating pre‐vaccination titres of \>1/40 in 30% of the pre‐dialysis patients, 60% of the peritoneal dialysis patients, 25% of the haemodialysis patients and 13·5% of the renal transplant recipients. Although this seroprotection rate was lower than that in healthy population,[^16^](#b16){ref-type="ref"} these results demonstrate a highly dissimilar pre‐existing level of immunity in the four groups of renal patients before vaccination and suggest that the response to A(H1N1) pdm09 could be influenced by the differential immunological status amongst these four types of renal replacement therapy. Notably, in this study, the overall rate of seroconversion and seroprotection in pre‐dialysis, haemodialysis and peritoneal dialysis patients after two vaccine doses reached the targets reported in the literature for an optimal response after one dose of the seasonal vaccination in healthy subjects or with controlled chronic illness. In contrast, the seroprotection rate after two doses of the A(H1N1) pdm09 vaccine was sub‐optimal in renal transplant recipients showing a pre‐vaccination titre \<1/40.

Compared with vaccination in dialysis patients, renal recipients had a lower antibody titre and an inability to maintain adequate antibody titres over time. Indeed, in both the pre‐dialysis and peritoneal dialysis groups, the seroprotection rate after two vaccine doses was 100%, showing that the vaccine efficacy in these groups of renal patients was similar to that in the general population vaccinated with a single dose.[^16^](#b16){ref-type="ref"} The seroconversion rate in the peritoneal dialysis population was lower because 6 of the 14 patients in this group had a pre‐existing seroprotection level of \>1/40 before vaccination.

There is little information on the effects of dialysis dose on seroconversion after vaccination. However, apart from the use of two vaccine doses, a better and more homogeneous antibody response after vaccination in these haemodialysis patients could be related to the fact that they received high‐flux haemodialysis and had optimum dialysis adequacy (Kt \>45 l). Indeed, Crespo *et al.* [^15^](#b15){ref-type="ref"} recently reported that the seroconversion rate after one dose of the vaccine was only 33% in haemodialysis patients receiving a lower dialysis dose (Kt/*V* single pool 1·8).

Renal transplantation is the standard of care for patients with ESRD. Recent improvements in kidney transplantation have been driven largely by lower acute rejection rates and better long‐term graft survival attributed to immunosuppressive agents. Standard immunosuppressive protocols to prevent acute graft rejection in this setting involve three major groups of drugs: CNI, anti‐metabolites and steroids. There is no doubt that corticosteroids and CNI are the cornerstone of these therapeutic protocols and have played an important role in improving graft survival, mainly because of the reduction of acute rejection episodes.[^17^](#b17){ref-type="ref"} In transplant recipients, influenza can range from a mild illness to severe lower respiratory tract disease, and immunization of target groups was recommended as an effective way to reduce the impact of the 2009--2010 influenza pandemic.[^18^](#b18){ref-type="ref"} Analysis of the data reported in this work supports previous observations indicating that the level of immunosuppression seems to be an important variable determining the antibody response to a vaccine. Salles *et al.* [^19^](#b19){ref-type="ref"} showed that the use of MMF decreased the immune response to seasonal influenza vaccine, although other studies showed no influence of the type of immunosuppressive therapy on seroconversion rate after A(H1N1) pdm09 vaccine.[^14^](#b14){ref-type="ref"}, [^15^](#b15){ref-type="ref"} A striking finding was that, in this cohort, immunosuppression consisting of triple therapy with MMF + CNI+ steroids had a deleterious effect on the antibody response to the vaccine, even when two vaccine doses were used in these recipients; this negative impact was more marked when we analysed the isolated influence of steroid therapy on the immunogenicity to this vaccination protocol.

In general, for influenza vaccination in other conditions, studies suggest that immunosuppressive medications may partially dampen the immune response, particularly when multiple immunosuppressive medications are used.[^20^](#b20){ref-type="ref"} This work suggests that strong immunosuppression may be responsible for a lower response to the vaccine in transplant recipients and looks like a dose--response effect as the number of agents rises from mono to triple therapy, but additional studies are required to confirm this possibility.

With seasonal influenza vaccine, there has been anecdotal concern for vaccine‐triggered allograft rejection.[^21^](#b21){ref-type="ref"}, [^22^](#b22){ref-type="ref"}. However, immunogenicity and safety studies of influenza vaccine in transplant patients to date have not shown an increased risk of rejection, and epidemiologic data have not supported an association between vaccination and allograft rejection. In this study, vaccination with Pandemrix^®^ was well tolerated, only a few mild reactions occurred, and there were no episodes of acute graft rejection. However, experience with the safety of novel vaccine adjuvants in transplantation is limited and should be analysed in larger and prospective studies.

Pandemrix is combined with the proprietary ASO3 adjuvant and designed specifically to induce an increased antibody response. Traditional influenza A vaccine is not adjuvanted, and the qualitative effects of the adjuvant on the immune response may be important in relation to the effect of immunosuppressive drugs on the antibody response. The paper by Salles [^19^](#b19){ref-type="ref"} used seasonal vaccine that does not contain an adjuvant, whilst the work of Labriola [^14^](#b14){ref-type="ref"} and Crespo [^15^](#b15){ref-type="ref"} used Pandemrix. Although in both cases, transplant patients responded less well than dialysis patients when vaccinated, certain formulations may work better in transplant patients than others and could be investigated in the near future.

These data question the efficacy of the A(H1N1) pdm09 vaccine in transplant patients under triple immunosuppression therapy and demonstrate the need for new studies with a larger population of renal transplant recipients to evaluate the efficacy and safety profile of the vaccine in these patients before issuing a general recommendation.

In conclusion, the results reported herein show that immune response to one and two doses of the A(H1N1) pdm09 vaccine is dissimilar in the four renal replacement therapy conditions, confirming that seroprotection in pre‐dialysis, haemodialysis and peritoneal dialysis is similar to that in the general population vaccinated with one dose. These data corroborate that, as reported in children under 12 years of age,[^23^](#b23){ref-type="ref"} ESRD and dialysis patients require two doses for adequate protection.

In contrast, renal transplant recipients with good allograft function and under heavy immunosuppression showed inadequate protection after two doses of the vaccine and triple immunosuppressive therapy including calcineurin inhibitors (ACI), MMF and steroids negatively influenced seroconversion after vaccination in renal recipients. In particular, steroid therapy was of importance in this cohort.
